Neon Therapeutics is a clinical-stage immuno-oncology company leading in the field of neoantigen-targeted therapies and dedicated to transforming the treatment of each patient’s cancer by directing the immune system towards neoantigens. We have pioneered a proprietary neoantigen platform to develop neoantigen-targeted therapies using two distinct approaches. In NEON / ONE, these neoantigens are specific to each individual. In NEON / SELECT, these neoantigens are shared across subsets of patients and tumor types. Our most advanced product candidate is NEO‑PV‑01, a personal neoantigen vaccine, that is currently being evaluated in a Phase 1b open‑label clinical trial for patients with metastatic melanoma, non‑small cell lung cancer or bladder cancer.
Events & Presentations
Jul 15, 2019 at 8:30 AM EDT
Jun 7, 2019 at 12:30 PM EDT
May 15, 2019 at 5:00 PM PDT
July 15, 2019Neon Therapeutics’ Personal Neoantigen Vaccine Study Demonstrates Prolonged Progression-Free Survival in Advanced or Metastatic Melanoma, Non-Small Cell Lung and Bladder Cancers
June 3, 2019Neon Therapeutics to Present at Jefferies 2019 Healthcare Conference
May 13, 2019Neon Therapeutics Reports First Quarter 2019 Financial Results and Provides Clinical Update